Related Experiment Video
Updated: Jan 18, 2026
Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
Published on: September 15, 2017
Decoding the Inflammatory Pathway in Heart Failure: The Role of Interleukins and Tumor Necrosis Factor-Alpha in
Sameh A Ahmed1, Hussein M Ismail2, Ahmed B Alahmedi3
1Department of Pharmacognosy and Pharmaceutical Chemistry, College of Pharmacy, Taibah University, Al-Madinah Al-Munawarah 30001, Saudi Arabia.
Insights
Heart failure (HF) patients show higher levels of key inflammatory cytokines, including interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). These elevated markers correlate with reduced left ventricular ejection fraction (LVEF) and increased HF severity.
Area of Science:
- Cardiology
- Immunology
- Biochemistry
Background:
- Heart failure (HF) is a significant global health issue with substantial economic impact.
- Systemic inflammation, driven by cytokines like IL-1, IL-6, and TNF-α, is increasingly recognized as a key factor in HF pathophysiology.
- These inflammatory mediators contribute to disease progression and diminished cardiac function.
Purpose of the Study:
- To compare serum levels of IL-1, IL-6, and TNF-α in HF patients versus healthy controls.
- To investigate the relationship between these inflammatory markers and left ventricular ejection fraction (LVEF) in HF.
- To assess the association between inflammatory mediator levels and HF severity.
Main Methods:
- A case-control study involving 61 HF patients and 65 controls was conducted.
- Serum concentrations of IL-1, IL-6, and TNF-α were quantified using enzyme-linked immunosorbent assay (ELISA).
- Clinical data, including LVEF and echocardiographic findings, were systematically recorded and analyzed.
Main Results:
- HF patients exhibited significantly higher serum levels of IL-1, IL-6, and TNF-α compared to controls (p < 0.001 for all).
- Elevated inflammatory marker levels were strongly associated with lower LVEF.
- Higher cytokine concentrations correlated with more advanced New York Heart Association (NYHA) functional classes.
Conclusions:
- The study confirms a significant elevation of IL-1, IL-6, and TNF-α in HF patients, underscoring inflammation's critical role.
- Findings suggest a direct link between systemic inflammation, HF progression, and impaired cardiac function.
- This research provides insights into HF's inflammatory mechanisms, potentially guiding future therapeutic strategies.
Abstract:
Background/Objectives: Heart failure (HF) remains a major global cause of morbidity and mortality, exerting substantial health and economic burdens. Increasing evidence suggests that systemic inflammation plays a pivotal role in HF pathophysiology, with key cytokines; interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) contributing to disease progression and worsening cardiac function. This study aimed to evaluate serum levels of IL-1, IL-6, and TNF-α in patients with HF compared to control subjects, to assess differences in these inflammatory mediators between groups, and to explore their relationship with left ventricular ejection fraction (LVEF). Methods: A case-control study was conducted at the Madinah Cardiac Center between October 2024 and April 2025, including 61 patients diagnosed with HF and 65 age- and sex-matched controls without HF. Serum concentrations of IL-1, IL-6, and TNF-α were measured using enzyme-linked immunosorbent assay (ELISA). Clinical parameters, including LVEF and echocardiographic data, were recorded and analyzed. Results: Patients with HF demonstrated significantly elevated levels of IL-1 (6.77 ± 1.17 vs. 1.27 ± 0.42 pg/mL, p < 0.001), IL-6 (54.12 ± 4.64 vs. 9.29 ± 1.72 pg/mL, p < 0.001), and TNF-α (235.56 ± 18.88 vs. 67.37 ± 6.28 pg/mL, p < 0.001) compared to controls. Higher inflammatory marker levels were associated with reduced LVEF and more advanced New York Heart Association (NYHA) functional class, indicating a clear link between systemic inflammation and HF severity. Conclusions: The significant elevation of IL-1, IL-6, and TNF-α in HF patients highlights the pivotal role of inflammation in disease progression and severity, offering valuable insights into the underlying mechanisms that may inform future therapeutic strategies. By providing a comprehensive evaluation of these key pro-inflammatory cytokines in relation to LVEF, this study presents an integrated perspective on the inflammatory profile associated with HF.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
01:17Pathophysiology of Heart Failure
01:21Myocarditis I: Introduction
01:28Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
01:20The JAK-STAT Signaling Pathway
01:30Heart Failure IV: Classification and Diagnostic Evaluation